kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2014-1-59-66kpccz-29Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEПРОФИЛАКТИКА ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ ПОСЛЕ КАТЕТЕРНОЙ АБЛАЦИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ С ПОМОЩЬЮ ДАБИГАТРАНАPREVENTION OF THROMBOEMBOLIC COMPLICATIONS AFTER ATRIAL FIBRILLATION CAT HETER ABLATION USING DABIGATRANМамчурС. Е.MamchurS. E.

доктор медицинских наук

заведующий лабораторией нарушений ритма сердца и электрокардиостимуляции

Адрес для переписки:Мамчур С. Е., 650002, г. Кемерово, Сосновый бульвар, д. 6. Тел. 8(3842) 64-35-38

Dr. Med. Sci.

head of the laboratory of violations of a rhythm of heart and electrocardiostimulation

Correspondence address:S. E. Mamchur, 6, Sosnoviy blvd., Kemerovo, 650002. Tel. +7 (3842) 64-35-38

mamchse@cardio.kem.ruГорбуноваЕ. В.GorbunovaE. V.ЩербининаД. А.ScherbininaD. A.РомановаМ. П.RomanovaM. P.Федеральное государственное бюджетное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» Сибирского отделения Российской академии медицинских наук, КемеровоРоссияResearch Institute for Complex Issues of Cardiovascular Disease, KemerovoRussian Federation201428062015015966Copyright © Мамчур С.Е., Горбунова Е.В., Щербинина Д.А., Романова М.П., 20152015Мамчур С.Е., Горбунова Е.В., Щербинина Д.А., Романова М.П.Mamchur S.E., Gorbunova E.V., Scherbinina D.A., Romanova M.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/29

В обзорной статье освещены результаты наиболее крупных исследований, касающиеся сравнения эффективности и безопасности применения дабигатрана и варфарина для профилактики тромбоэмболических осложнений у пациентов, подвергшихся радиочастотной катетерной аблации фибрилляции предсердий.

In the survey, the results of the largest comparative studies on the efficacy and safety of dabigatran and warfarin for the prevention of thromboembolic complications in patients underwent atrial fibrillation catheter ablation are discussed.

фибрилляция предсердийкатетерная аблацияварфариндабигатранatrial fibrillationcatheter ablationwarfarindabigatranReferencesДиагностика и лечение фибрилляции предсердий: рекомендации РКО, ВНОА и АССХ / Рос. кардиол. об-во, Всерос. науч. об-во специалистов по клин. электрофизиологии, аритмологии и кардиостимуляции, Ассоц. сердечно-сосудистых хирургов. М., 2012. 100 с.Диагностика и лечение фибрилляции предсердий: рекомендации РКО, ВНОА и АССХ / Рос. кардиол. об-во, Всерос. науч. об-во специалистов по клин. электрофизиологии, аритмологии и кардиостимуляции, Ассоц. сердечно-сосудистых хирургов. М., 2012. 100 с.Клинические рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств. Изд. 4-е. М.: ГЭОТАР-Медиа, 2013. 596 с.Клинические рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств. Изд. 4-е. М.: ГЭОТАР-Медиа, 2013. 596 с.A Head-to-Head Comparison of Periprocedural Coagulability Under Anticoagulation with Rivaroxaban Versus Dabigatran in Patients Undergoing Ablation of Atrial Fibrillation / A. Sairaku [et al.] // Clin. Drug. Investig. 2013. Vol. 33. P. 847–853.A Head-to-Head Comparison of Periprocedural Coagulability Under Anticoagulation with Rivaroxaban Versus Dabigatran in Patients Undergoing Ablation of Atrial Fibrillation / A. Sairaku [et al.] // Clin. Drug. Investig. 2013. Vol. 33. P. 847–853.Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study / S. Kapa [et al.] // J. Cardiovasc. Electrophysiol. 2013. Vol. 24 (8). P. 875–881.Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study / S. Kapa [et al.] // J. Cardiovasc. Electrophysiol. 2013. Vol. 24 (8). P. 875–881.Catheter Ablation of Atrial Fibrillation Without Dabigratan Discontinuation: Preliminary Safety and Efficacy Data / L. Di Biaise [et al.] // Circulation. 2011. Vol. 124. P. A14277.Catheter Ablation of Atrial Fibrillation Without Dabigratan Discontinuation: Preliminary Safety and Efficacy Data / L. Di Biaise [et al.] // Circulation. 2011. Vol. 124. P. A14277.Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation / S. Schneeweiss [et al.] // Cardiovasc Qual Outcomes. 2012. Vol. 5(4). P. 480–486.Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation / S. Schneeweiss [et al.] // Cardiovasc Qual Outcomes. 2012. Vol. 5(4). P. 480–486.Dabigatran in patients post atrial fibrillation ablation / C. Eitel [et al.] // JACC. 2012. Vol. 59. Abstr. 1235–1296.Dabigatran in patients post atrial fibrillation ablation / C. Eitel [et al.] // JACC. 2012. Vol. 59. Abstr. 1235–1296.Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness / A. R. Kansal [et al.] // Thromb Haemost. 2012. Vol. 108(4). P. 672–682.Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness / A. R. Kansal [et al.] // Thromb Haemost. 2012. Vol. 108(4). P. 672–682.Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion / R. Nagarakanti [et al.] // Circulation. 2011. Vol. 123. P. 131–136.Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion / R. Nagarakanti [et al.] // Circulation. 2011. Vol. 123. P. 131–136.Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation / J. S. Kim [et al.] // Heart Rhythm. 2013. Vol. 10. P. 483–489.Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation / J. S. Kim [et al.] // Heart Rhythm. 2013. Vol. 10. P. 483–489.Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study / A. Verma [et al.] // JAMA Intern. Med. 2013. Vol. 173(2). P. 149–156.Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study / A. Verma [et al.] // JAMA Intern. Med. 2013. Vol. 173(2). P. 149–156.Feasibility & Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation: Results from a Multicenter Prospective Registry / D. Lakkireddy [et al.] // J. Am. Coll. Cardiol. 2013. pii: S0735-1097(13)06543-1. [Epub ahead of print].Feasibility & Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation: Results from a Multicenter Prospective Registry / D. Lakkireddy [et al.] // J. Am. Coll. Cardiol. 2013. pii: S0735-1097(13)06543-1. [Epub ahead of print].Hohnloser S. H., Camm A. J. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature // Europace. 2013. Vol. 15 (10). P. 1407–1411.Hohnloser S. H., Camm A. J. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature // Europace. 2013. Vol. 15 (10). P. 1407–1411.HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design / H. Calkins [et al.] // Europace. 2012. Vol. 14. P. 528–606.HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design / H. Calkins [et al.] // Europace. 2012. Vol. 14. P. 528–606.Impact of atrial fibrillation on the risk of death: the Framingham Heart study / E. J. Benjamin [et al.] // Circulation. 1998. Vol. 98. P. 946–952.Impact of atrial fibrillation on the risk of death: the Framingham Heart study / E. J. Benjamin [et al.] // Circulation. 1998. Vol. 98. P. 946–952.Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study / C. Herrera Siklódy // J. Am. Coll. Cardiol. 2011. Vol. 58(7). P. 681–688.Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study / C. Herrera Siklódy // J. Am. Coll. Cardiol. 2011. Vol. 58(7). P. 681–688.Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation / G. Y. H. Lip // J. Am. Coll. Cardiol. 2012. Vol. 60. P. 738–746.Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation / G. Y. H. Lip // J. Am. Coll. Cardiol. 2012. Vol. 60. P. 738–746.Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial / J. P. Piccini [et al.] // J. Am. Coll. Cardiol. 2013. Vol. 61. P. 1998–2006.Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial / J. P. Piccini [et al.] // J. Am. Coll. Cardiol. 2013. Vol. 61. P. 1998–2006.Pradaxa Can Be Safely Used As Monotherapy Or As A Bridge To Therapeutic Warfarin After Atrial Fibrillation Ablation / T. J. Bunch [et al.] // Circulation. 2011. Vol. 124. P. A14708.Pradaxa Can Be Safely Used As Monotherapy Or As A Bridge To Therapeutic Warfarin After Atrial Fibrillation Ablation / T. J. Bunch [et al.] // Circulation. 2011. Vol. 124. P. A14708.Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications / W. M. Feinberg [et al.] // Arch. Intern. Med. 1995. Vol. 155. P. 469–473.Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications / W. M. Feinberg [et al.] // Arch. Intern. Med. 1995. Vol. 155. P. 469–473.Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation / J. Cosedis Nielsen [et al.] // N. Engl. J. Med. 2012. Vol. 367 (17). P. 1587–1595.Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation / J. Cosedis Nielsen [et al.] // N. Engl. J. Med. 2012. Vol. 367 (17). P. 1587–1595.Radiofrequency ablation vs antiarrhythmic drugs as firstline treatment of symptomatic atrial fibrillation: A randomized trial / O. M. Wazni [et al.] // JAMA. 2005. Vol. 293. Р. 2634–2640.Radiofrequency ablation vs antiarrhythmic drugs as firstline treatment of symptomatic atrial fibrillation: A randomized trial / O. M. Wazni [et al.] // JAMA. 2005. Vol. 293. Р. 2634–2640.Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins / M. Haissaguerre [et al.] // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins / M. Haissaguerre [et al.] // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study / T. J. Wang [et al.] // Circulation. 2003. Vol. 107. P. 2920–2925.Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study / T. J. Wang [et al.] // Circulation. 2003. Vol. 107. P. 2920–2925.The use of dabigatran immediately after atrial fibrillation ablation / R. A. Winkle [et al.] // J. Cardiovasc. Electrophysiol. 2012. Vol. 23. P. 264–268.The use of dabigatran immediately after atrial fibrillation ablation / R. A. Winkle [et al.] // J. Cardiovasc. Electrophysiol. 2012. Vol. 23. P. 264–268.Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses / H. Calkins [et al.] // Circ. Arrhythm. Electrophysiol. 2009. Vol. 2. P. 349–361.Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses / H. Calkins [et al.] // Circ. Arrhythm. Electrophysiol. 2009. Vol. 2. P. 349–361.Use of Dabigatran for Peri-Procedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial fibrillation: A New Paradigm in Peri-Procedural Anticoagulation / M. Bassiouny [et al.] // Circulation. 2011. Vol. 124. P. A13128.Use of Dabigatran for Peri-Procedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial fibrillation: A New Paradigm in Peri-Procedural Anticoagulation / M. Bassiouny [et al.] // Circulation. 2011. Vol. 124. P. A13128.Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation / H. Yamaji [et al.] // Clin. Drug. Investig. 2013. Vol. 33. P. 409–418.Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation / H. Yamaji [et al.] // Clin. Drug. Investig. 2013. Vol. 33. P. 409–418.

The authors declare that there are no conflicts of interest present.